help button home button Endocrine Society JCEM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH

This version published online on January 11, 2005
Journal of Clinical Endocrinology & Metabolism, doi:10.1210/jc.2004-1325
A more recent version of this article appeared on April 1, 2005
This Article
Right arrow Author Manuscript (PDF)
Right arrow All Versions of this Article:
90/4/2250    most recent
Author Manuscript (PDF)
Right arrow Submit a related Letter to the Editor
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by MacLean, P. S.
Right arrow Articles by Barakat, H. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by MacLean, P. S.
Right arrow Articles by Barakat, H. A.

Submitted on July 8, 2004
Accepted on January 4, 2005

Suppression of hepatic CETP expression in obese humans with the development of type 2 diabetes mellitus

Paul S. MacLean*, Satyaprasad Vadlamudi, Kenneth G. MacDonald, Walter J. Pories, and Hisham A. Barakat

Center for Human Nutrition and the Department of Medicine, Division of Endocrinology, Metabolism, and Diabetes, in the University of Colorado Health Sciences Center, Denver, CO; Departments of Biochemistry, Surgeryand Internal Medicinein the Brody School of Medicine, East Carolina University, Greenville, NC

* To whom correspondence should be addressed. E-mail: Paul.maclean{at}uchsc.edu.

Cholesteryl ester transfer protein (CETP) is a plasma enzyme that can modulate the profile of lipoproteins and is thus considered a: 1) mediator of vascular disease; and 2) therapeutic target for vascular disease. In the present study we pursued a better understanding of the effect of type 2 diabetes on the expression of CETP in obese patients. Obesity was accompanied by a 20% elevation in plasma CETP that was eliminated with the development of diabetes. These differences were observed for both men and women and were due to variations in the amount of CETP protein in the plasma. The mRNA and protein of both the full length (CETPFL) and alternatively spliced (CETP{Delta}9) forms of CETP were lower in the liver, but not in either sc or omental adipose tissue depots, of diabetic obese subjects. Sterol response element binding proteins 1 and 2 were also lower in liver homogenates, suggesting that these transcription factors may mediate the effects of type 2 diabetes on hepatic CETP expression. Thus, the suppressive effects of type 2 diabetes in obese subjects is observed in both men and women and may be due, at least in part, to a suppression of hepatic CETP expression.


Key words: Leptin • insulin resistance • SREBP • glucose • morbid obesity




This article has been cited by other articles:


Home page
J. Lipid Res.Home page
M. E. Lira, A. K. Loomis, S. A. Paciga, D. B. Lloyd, and J. F. Thompson
Expression of CETP and of splice variants induces the same level of ER stress despite secretion efficiency differences
J. Lipid Res., September 1, 2008; 49(9): 1955 - 1962.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Regul. Integr. Comp. Physiol.Home page
M. R. Jackman, A. Steig, J. A. Higgins, G. C. Johnson, B. K. Fleming-Elder, D. H. Bessesen, and P. S. MacLean
Weight regain after sustained weight reduction is accompanied by suppressed oxidation of dietary fat and adipocyte hyperplasia
Am J Physiol Regulatory Integrative Comp Physiol, April 1, 2008; 294(4): R1117 - R1129.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
S. Fazio and M. F. Linton
Sorting Out The Complexities of Reverse Cholesterol Transport: CETP Polymorphisms, HDL, and Coronary Disease.
J. Clin. Endocrinol. Metab., September 1, 2006; 91(9): 3273 - 3275.
[Full Text] [PDF]


Home page
Am. J. Physiol. Regul. Integr. Comp. Physiol.Home page
P. S. MacLean, J. A. Higgins, M. R. Jackman, G. C. Johnson, B. K. Fleming-Elder, H. R. Wyatt, E. L. Melanson, and J. O. Hill
Peripheral metabolic responses to prolonged weight reduction that promote rapid, efficient regain in obesity-prone rats
Am J Physiol Regulatory Integrative Comp Physiol, June 1, 2006; 290(6): R1577 - R1588.
[Abstract] [Full Text] [PDF]


Home page
DiabetesHome page
R. de Vries, F. G. Perton, G. M. Dallinga-Thie, A. M. van Roon, B. H.R. Wolffenbuttel, A. van Tol, and R. P.F. Dullaart
Plasma Cholesteryl Ester Transfer Is a Determinant of Intima-Media Thickness in Type 2 Diabetic and Nondiabetic Subjects: Role of CETP and Triglycerides
Diabetes, December 1, 2005; 54(12): 3554 - 3559.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 2005 by The Endocrine Society